Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
Por:
Sanchez-Garcia, J, del Canizo, C, Lorenzo, I, Nomdedeu, B, Luno, E, de Paz, R, Xicoy, B, Valcarcel, D, Brunet, S, Marco-Betes, V, Garcia-Pintos, M, Osorio, S, Tormo, M, Bailen, A, Cervero, C, Ramos, F, Diez-Campelo, M, Such, E, Arrizabalaga, B, Azaceta, G, Bargay, J, Arilla, MJ, Falantes, J, Serrano-Lopez, J, Sanz, GF
Publicada:
1 jul 2014
Resumen:
The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear. This study used time-dependent multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia (AML) progression in 215 patients with International Prognostic Scoring System (IPSS) low or intermediate-1 risk and del(5q). There were significant differences in several relevant characteristics at presentation between patients receiving (n = 86) or not receiving lenalidomide (n = 129). The 5-year time-dependent probabilities of OS and progression to AML were 62% and 31% for patients receiving lenalidomide and 42% and 25% for patients not receiving lenalidomide; differences were not statistically significant in multivariate analysis that included all variables independently associated with those outcomes (OS, P = 0.45; risk of AML, P = 0.31, respectively). Achievement of RBC transfusion independency (P = 0.069) or cytogenetic response (P = 0.021) after lenalidomide was associated with longer OS in multivariate analysis. These data clearly show that response to lenalidomide results in a substantial clinical benefit in lower risk MDS patients with del(5q). Lenalidomide treatment does not appear to increase AML risk in this population of patients.
Filiaciones:
Sanchez-Garcia, J:
Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Cordoba, Spain
del Canizo, C:
Hosp Univ Salamanca, Salamanca, Spain
Lorenzo, I:
Hosp Univ & Politecn La Fe, Valencia, Spain
Nomdedeu, B:
Hosp Clin Barcelona, Barcelona, Spain
Luno, E:
Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
de Paz, R:
Hosp Univ La Paz, Madrid, Spain
Xicoy, B:
Hosp Badalona Germans Trias & Pujol, Josep Carreras Res Inst, Inst Catala Oncol, Badalona, Spain
Valcarcel, D:
Hosp Univ Vall dHebron, Barcelona, Spain
Brunet, S:
Univ Autonoma Barcelona, Hosp St Pau, E-08193 Barcelona, Spain
Marco-Betes, V:
Hosp Arnau Vilanova, Lerida, Spain
Garcia-Pintos, M:
Consorci Sanitari Terrassa, Terrassa, Spain
Osorio, S:
Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Tormo, M:
Hosp Clin Univ, Inst Invest INCLIVA, Valencia, Spain
Bailen, A:
Hosp Univ Carlos Haya, Malaga, Spain
Cervero, C:
Hosp Virgen Luz, Cuenca, Spain
Ramos, F:
Hosp Univ Leon, Leon, Spain
Univ Leon, IBIOMED, E-24071 Leon, Spain
Diez-Campelo, M:
Hosp Univ Salamanca, Salamanca, Spain
Such, E:
Hosp Univ & Politecn La Fe, Valencia, Spain
Arrizabalaga, B:
Hosp Univ Cruces, Baracaldo, Spain
Azaceta, G:
Hosp Clin Univ Lozano Blesa, Zaragoza, Spain
Bargay, J:
Hosp Son Llatzer, Palma De Mallorca, Spain
Arilla, MJ:
Hosp Sagunto, Sagunto, Spain
Falantes, J:
Hosp Univ Virgen del Rocio, Seville, Spain
Serrano-Lopez, J:
Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Cordoba, Spain
Sanz, GF:
Hosp Univ & Politecn La Fe, Valencia, Spain
Bronze
|